Article

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

2023-12-09

Abstract excerpt

<h4>ABSTRACT</h4> Inotuzumab ozogamicin (InO) is an antibody-drug conjugate that delivers calicheamicin to CD22-expressing cells. In a retrospective cohort of InO treated patients with B-cell acute lymphoblastic leukemia, we sought to understand the genomic determinants of response to InO. Acquired CD22 mutations were observed in 11% (3/27) of post-InO relapsed tumor samples. There were multiple CD22 mutations per...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0fa34c9a-77af-5e99-91f2-4490fe585c62
DOI: 10.1101/2023.12.06.23299616

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALLDOI 10.1101/2023.12.06.23299616Read

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.Semantic proximity Read

Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicinSemantic proximity Read

Case Report: Immune-driven clonal selection underlying lineage switch from B-Precursor acute lymphoblastic leukemia to acute myeloid leukemia following inotuzumab ozogamicin.Semantic proximity Read

DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaSemantic proximity Read

Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALL.Semantic proximity Read

Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53Semantic proximity Read

IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemiaSemantic proximity Read

Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma.Semantic proximity Read

Unraveling Cellular and Molecular Mechanisms of Relapse in CD19/CD22 Dual-Targeting CAR T Therapy for B-ALLSemantic proximity Read

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemiaSemantic proximity Read

Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell DysfunctionSemantic proximity Read

Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Semantic proximity Read